Updated Data With Larotrectinib in TRK Fusion-Positive Solid Tumors
David S. Hong, MD, discusses updated data with larotrectinib (Vitrakvi) in <em>TRK</em> fusion-positive solid tumors at the ESMO Congress 2019.
David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses updated data with larotrectinib (Vitrakvi) in TRKfusion-positive solid tumors at the ESMO Congress 2019.
The tumor-agnostic TRK inhibitor larotrectinib showed sustained antitumor activity in adult and pediatric patients withTRKfusionpositive cancers, based on updated findings from an integrated analysis of an adult phase I trial, the phase I/II SCOUT pediatric trial, and the phase II adult/adolescent NAVIGATE basket trial.
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
